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Background Uncontrolled studies have shown that short
atrioventricular delay dual chamber pacing reduces outflow
tract obstruction in hypertrophic obstructive cardiomyo-
pathy. Although the exact mechanism of this beneficial
effect is unclear, this seems a promising potential new
treatment for hypertrophic obstructive cardiomyopathy.
Method In order to evaluate the impact of pacing therapy,
we performed a randomized multicentre double-blind cross-
over (pacemaker activated vs non activated) study to inves-
tigate modification of echocardiography, exercise tolerance,
angina, dyspnoea and quality of life in 83 patients with
a mean age of 53 (range 22-87) years with symptoms
refractory or intolerant to classical drug treatment.
Results After 12 weeks of activated or inactivated pacing,
independent of which phase was first, the pressure gradient
fell from 59 ± 36 mmHg to 30 ± 25 mmHg (P<0001) with
active pacing.
Exercise tolerance improved by 21% in those patients who
at baseline tolerated less than 10 min of Bruce protocol;
symptoms of dyspnoea and angina also improved signifi-
cantly from NYHA class 2-4 to 1-4 and 10 to 0-4, respect-
ively (/"<0007). Quality of life assessment with a validated
questionnaire objectivated the subjective improvement.
Conclusion Pacemaker therapy is of clinical and haemo-
dynamic benefit for patients with hypertrophic obstruc-
tive cardiomyopathy, left ventricular outflow gradient at
rest over 30 mmHg who are symptomatic despite drug
treatment.
(Eur Heart J 1997; 18: 1249-1256)
Key Words: Hypertrophic obstructive cardiomyopathy,
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Introduction
Hypertrophic cardiomyopathy is a primary cardiac dis-
ease genetically transmitted as an autosomal dominant
trait with variable penetrance, and, additionally, there is
a high proportion of sporadic non-familial cases'1"31. It is
characterized by ventricular hypertrophy with myocyte
and myofibrillar disarray. Molecular genetic studies
have revealed the chromosomal locus and allowed iso-
lation of several putative genes leading to mutations in
the beta cardiac myosin heavy chain'4"6'. Penetration is
heterogeneous, as are the phenotypic manifestations.
Hypertrophic cardiomyopathy presents in various
forms, but usually as an asymmetric hypertrophy which
can be located in the subaortic, midventricular or apical
regions and also elsewhere in the right or left ven-
tricles'7'. The hypertrophy causes several pathophysio-
logical features including a hypercontractile state,
diastolic dysfunction'81, disturbed coronary flow with
ischaemic'9""' and also abnormal responses of the
peripheral vasculature to exercise1'2'. In the obstructive
form of hypertrophic cardiomyopathy, there are both
septal thickening in the subaortic region and functional
abnormalities of the mitral valve apparatus'13141 of
which systolic anterior movement of the anterior cusp is
the most prominent.
Two principal mechanisms for systolic anterior
movement have been proposed, first the Venturi mech-
anism, by which the hypertrophied septum induces
acceleration of blood flow which sucks the anterior cusp
towards it resulting in a further narrowing of left
ventricular outflow. This phenomenon may be com-
pounded by elongated tendons and a floppy valve. All
this results in an obstruction and consequently pressure
gradient across the outflow tract1'5"171. Second, the
anatomical alterations in the mitral valve apparatus,
particularly the anterior displacement of the papillary
muscle, approximation of the anterior cusp to the
septum exposing it to flow drag1'81, again results in
obstruction. Inversion of the ventricular activation
sequence by right apical pacing can, in part, eliminate
these deleterious events'2'1.
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Clinical observations have led to a haemo-
dynamic classification of hypertrophic obstructive
cardiomyopathy'71 where obstruction may be persistent
(at rest) labile (variable) or latent (provocable). The
symptoms of hypertrophic obstructive cardiomyopathy
typically include dyspnoea which relates to diastolic
dysfunction, angina due to ischaemia, and syncope or
exertional dizziness caused by obstruction, arrhythmia
and/or inappropriate behaviour of the peripheral circu-
lation. The severity of symptoms does not necessarily
correlate with the left ventricular outflow gradient.
However, patients with non-obstructive hypertrophic
cardiomyopathy usually present with fewer and milder
symptoms'131.
Treatment of hypertrophic obstructive cardio-
myopathy so far has been either pharmacological (beta-
blockers, calcium antagonists, disopyramide)'19'20'221
with the goal of reducing outflow obstruction and
improving ventricular relaxation and rhythm control, or
surgery (myotomy, myectomy and mitral valve recon-
struction) all offering an impressive gradient reduc-
tion[2]. The observation that electrical stimulation of the
heart has a beneficial effect on outflow obstruction was
first reported from acute pacing studies123"251. Sympto-
matic benefit and haemodynamic improvement was later
achieved in long-term studies126"281.
In order to investigate prospectively subjective
and objective effects of adding cardiac pacing to normal
medical treatment in hypertrophic obstructive cardio-
myopathy (PIC) we performed whenever possible a
double blinded randomized crossover, pacemaker active
vs non-active study in patients refractory or intolerant of
drugs who were considered to be candidates for surgery.
The following is a report of the crossover part of the
PIC Study. To our knowledge, this is the first blinded
randomized crossover study to investigate this effect of
pacing and to study a device using drug-trial standards.
Patients and methods
This multicentre study is conducted according to the
guidelines of the EN540, the European standard on
clinical investigation of medical devices for human sub-
jects, which includes compliance to the declaration of
Helsinki. The study was co-ordinated by the European
Working Group on Cardiac Pacing of the European
Society of Cardiology, and was accepted by the ethical
committees of each of the participating centres.
Patients with symptomatic hypertrophic obstruc-
tive cardiomyopathy refractory or intolerant to drug
treatment were evaluated. In general, they were referred
to the study centres for haemodynamic evaluation with a
view to surgical relief of obstruction. Inclusion criteria
were therefore functional limitation (NYHA Class II or
III), angina and/or dyspnoea, despite maximal tolerated
drug therapy. These patients underwent a screening
catheterization and/or an echocardiography study to
evaluate the effect of dual-chamber pacing on the resting
gradient. Pacing was considered if, at rest, there was a
subaortic obstruction with peak pressure gradient of
>30 mmHg with or without provocation. When acute
pacing was well tolerated (no fall in cardiac output or
aortic pressure), implantation of a permanent dual-
chamber pacing system was offered and the patient
included in the study when informed written con-
sent was obtained and the pacemaker implanted. The
patients were classified into Group A when the acute
study showed a peak gradient reduction of >30% or
Group B if there was less or no gradient modification.
The screening examinations also included graded tread-
mill exercise tests using a modified Bruce protocol. Only
patients with less than 85% of age-predicted VO2max
were considered suitable for the study. We excluded
patients with symptoms at rest corresponding to NYHA
Class IV, any severe valvular dysfunction not related
to systolic anterior movement, documented coronary
artery disease, age below 18 years, drug-refractory sys-
temic hypertension, ejection fraction <50%, chronic
atrial fibrillation and any patient where pacing was
indicated for another reason, except drug-induced
chronotropic incompetence.
Pacemakers
Any dual-chamber pulse generator could be used if it
incorporated the following programmable characteris-
tics: pacing modes including DDD and AAI lower rate
at 30 beats . min~', atrioventricular delay of 30 ms or
less to ensure complete ventricular capture, paced and
sensed atrioventricular delay separately programmable,
atrioventricular delay adaptation with increasing rate,
VVIR fall back mode in the event of atrial tachyarrhyth-
mias. Programming the pacemaker in DDD with opti-
mal atrioventricular delay was considered to be
pacemaker-activated; programming to AAI at 30 ppm
was termed pacemaker non-activated.
Study design
Both Groups A and B were stratified by central ran-
domization into two arms defining the sequence of
therapies. Randomization was active after the discharge
tests where the optimal atrioventricular delay was
identified in each patient (full ventricular capture on the
ECG without a drop in aortic pressure) and pacemaker
function verified. Programming in the active or passive
pacing arms of the study was not performed by the
investigator, to allow a double-blind design as accurate
as possible. After 12 weeks the two patient arms were
similarly assessed and their pacing modes inverted
(crossover). After the second 12-week period the two
groups were again reassessed, and, finally, the pacing
mode preferred by the patient was programmed for
long-term pacing.
The following assessment methods were used:
ECG, echocardiogram (left ventricular outflow tract
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pressure gradient, left ventricular dimensions, left
ventricular function, mitral valve movement and regur-
gitation, etc), 24-h ECG, symptom-limited exercise test
with measurement of spirometric and metabolic data.
For quality of life analysis, the Karolinska questionnaire
was used. Details on the questionnaire have previously
been described'29'. It has been validated for patients
paced for bradyarrhythmia and ischaemic heart disease.
Prior to the investigation, translations of this document
were validated against the original. The questionnaire
was administered by the technician or nurse and com-
pleted by the patient either at the clinic or at home at
screening and after each study period. In case of prema-
ture termination of one study arm a full evaluation
including quality of life was carried out. Medical history
focused on NYHA classification of global functional
capacity and the presence of syncope, fatigue, angina
and dyspnoea. Specific instructions on how to perform
each test and which parameters to measure were given to
each investigator. Programming of pacemakers was per-
formed double blind; neither the patient nor the investi-
gator were informed of the actual pacing mode. All
complications had to be specified and reported.
Statistical methods
The statistical tests included comparison between the
two arms (pacing vs non-pacing) as well as comparison
within a patient when tested after each of the 3 month
periods with pacing active vs non-active. All intra- and
interpatient comparisons included testing of type of
distribution (using Shapiro-Wilk or Kolmogorov-
Smirnov tests), and testing of significance of observed
differences (using the two-sided T-test, Wilcoxon Rank
sum, or Chi-square tests). A P-value of less than 005 is
considered significant. The quality of life was evalu-
ated with analysis of variance calculated by statistical
analysis system (SAS).
Results
A total of 83 patients was recruited for this study in 12
centres over a period of 24 months. There were 33
females and 50 males; mean age was 53 years (range
32-87). Drug treatment consisted of beta-blockers
taken by 42 patients, the average dose corresponding
to 150mg.day~' of propanolol; 39 were on cal-
cium antagonist (240 mg . day" ' of verapamil or equiv-
alent), 12 patients were administered Amiodarone
(200 mg . day"') , three disopyramide (300 mg) and
three various others. Diuretics were given to 10 patients
and three had ACE inhibitors. All drug prescriptions
remained unchanged over the whole crossover period.
At screening, haemodynamic and/or Doppler
echocardiographic measurements revealed that in 64
patients (77%) pacing induced an acute peak gradient
reduction of more than 30% (785 ± 31-9 mmHg to
32-4 ± 220 mmHg, Group A) while in 18 patients (22%)
it was less than 30% (853 ± 38-8 to 701 ± 351 mmHg,
Group B). Group B patients were younger (43 ± 14
years vs 56± 14 years P=00007). One patient died in
the screening phase due to right ventricular perforation
and cardiac tamponade before detailed measurements
could be made.
In order to confirm appropriate pacing, active as
well as non-active, a 24 h ECG was performed in 48 and
29 patients, respectively, at the end of each study arm.
Complete ventricular capture during the DDD phase
was present in >98% of ventricular complexes and atrial
pacing in either phase accounted for <1% of atrial
complexes. The atrioventricular delay for the DDD
phase was individually adapted and found optimal at
61 ± 23 ms for sensed atrial beats. No severe arrhyth-
mias were registered and the range from mean mini-
mal to maximal heart rate was 44 ± 8 beats . min ~ '
and 119 ± 27 beats . min ~ ' in pacemaker non-active
and 48 ± 6 beats . min ~ ' and 128 ± 20 beats . min ~ ' in
pacemaker active.
No syncope was reported during the 24 h ECG,
but two episodes occurred during the non-active and an
equal number during the active pacing phase.
The evolution of individual pressure gradients in
all patients is depicted in Fig. 1. The right panel shows
that after 3 months of DDD pacing, 38 out of the 40 full
documented patients had a decrease of the peak gradi-
ent. The mean reduction was 51%, from 53 mmHg to
26 mmHg (/><00001). Switching the pacemaker off
resulted in a re-increase of the gradient from 33 mmHg
to 59 mmHg (/><00001) in 35 of 36 patients. In seven
patients these measurements were not completed
because one died, two had technical problems and in
four the echocardiographic window was unreliable. In
Group B, the gradient decreased from 69 ± 39 mmHg to
45 ± 27 mmHg (/>=0004). Interestingly, in Group B the
gradient fell more than 30% in six patients (38%) in
contrast to their acute studies. At the end of 3 months of
activated pacing, the global ejection fraction in this
population remained unchanged.
The result of exercise duration analysis reveals
interesting findings (Fig. 2). Comparing the end of the
inactivated with the end of the activated phase, there is a
small but insignificant improvement. Subgroup analysis
of the more severely limited patients who had less than
10 min exertional tolerance with the inactive pacemaker,
however, showed that their walking time had signifi-
cantly improved by 21% (/><0008) once activated. No
difference in this respect could be demonstrated between
Groups A and B.
Symptoms were assessed by clinical history and
by a detailed double-blind validated quality of life
questionnaire1291. The overall functional class and evol-
ution of all patients is summarized in Fig. 3. Although
several patients reported episodes of resting symptoms
(NYHA Class IV), at the time of inclusion all corre-
sponded to Class II or III. One patient experienced a
brief deterioration and therefore entered Class IV with
the inactive pacemaker. Of the 28 patients in Class III
Eur Heart J, Vol. 18, August 1997
1252 L. Kappenberger et al.
140 -
120 -
100 -
- 140
-.120
- 100
DDD AAI AAI
^¥40
20
0
DDD
Figure 1 Evolution of peak outflow gradient in the DDD to AAI (n=36, /»<0-001) and AAI to DDD (n=40
/><0-001) phases; it made no difference which phase was first.
during the inactivated phase, 24 (84%) improved with
activated pacemakers and none deteriorated. Of the 37
in Class II, 17 (46%) improved with pacing activated and
one deteriorated. When compared with the baseline
findings at entry into the study, 20 of the 70 patients
already had some improvement although the pacemaker
was not activated. There was no difference with respect
to the sequence pacemaker first active or non-active.
Overall
analysis
Retrospective
subject analysis
AAI<=10
min
Figure 2 Duration of exercise tolerance activated ( • ) vs
non-activated (") pacemaker in all (Group A and B)
patients. There was no deterioration but patients with less
than 10 min at baseline or AAI benefited significantly with
a 21% increase of exercise duration.
Symptoms of dyspnoea and angina were similarly influ-
enced as shown in Fig. 4 and again there was no
difference between the sub-groups. Using intrapatient as
well as group comparisons the modifications induced by
the pacemaker active were highly significant on all
reported parameters (.P^OOOl), while inactivating the
pacemaker led to a significant deterioration. These sub-
jective findings were further substantiated by the quality
of life assessment with the validated quality of life
questionnaire in 81 patients. The relevant results are
summarised in Fig. 5. there was a greater improvement
in quality of life when the pacemaker was switched on
immediately than if it was turned on after 3 months,
reflecting some placebo-effect of this intervention.
Nevertheless, values of self-perceived symptomatology
document that with the pacemaker activated there was a
significant (/><0-05) improvement in the ability to self-
autonomy and strenuous physical activity, alertness and
cardiovascular symptomatology. Cognitive and sexual
functioning as well as emotional state were, however,
not significantly affected by the pacing mode.
Of the 83 patients included; 81 completed the
study, one died and one had surgery. Of the 41 ran-
domized to pacemaker active first, all completed a
12-week period. After inactivation of the pacemaker,
however, 14 returned prematurely to the clinic (1-83
days, mean 26 days) because of severe deterioration in
symptoms and self-perceived health status. At the end
of the crossover, 79 patients preferred pacing and two
more went to surgery. Of the 41 in pacemaker non-active
first, three returned to the clinic early because of no
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Figure 3 Pre-implant (baseline), non-activated (AAI) and activated
(DDD) limitation of functional capacity according to the NYHA
classification. Class III or IV were 60% at baseline, 41% with
non-activated and 7% with activated pacemaker.
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Figure 4 Overall modification of main symptoms according
to the NYHA classification of HOCM comparing the
activated (DDD) to the non-activated (AAI) period of the
patient.
improvement of symptoms, but when switching the
pacemaker to the active mode during a procedure
blinded for the patient and the investigating physician
(crossover), all completed their second 12-week arm of
the study. The majority of the 30 reported adverse events
were related to pacemaker treatment: infection and local
irritation (n = 8) or electrode displacements (7 atrial and
3 ventricular). Despite these problems, correct pace-
maker function was finally achieved in all patients. No
other minor event was related to pacing; one patient
was operated on during crossover phase for failure of
therapy.
Discussion
This study documents that pacing is beneficial in
patients with hypertrophic obstructive cardiomyopathy
and a resting gradient of more than 30 mmHg with
l -
p
p
p
- l
**
n
**
n
**
n
** **
*
n
Alertness Self Strenuous Self- Chest Dyspnoea
autonomy activity perceived pain
health
Figure 5 Comparison of grading quality of life and
cardiovascular symptomatology parameters between the
activated (DDD) and non-activated (AAI) period of the
study. Note in all parameters a significant preference for
the paced mode (* = 005 , ** 0 0 1 , *** 0001).
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symptoms refractory to conventional medical treatment.
Although we were able to document a placebo effect of
implanting a pacemaker and not activating it, the sub-
sequent effect of switching it on in a blinded manner
significantly improved symptoms, quality of life, and
exercise tolerance in those who are severely limited. The
reverse, inactivating the pacemaker, is even more im-
pressive as return of symptoms is more strongly felt by
the patients.
The haemodynamic benefit of dual chamber
short atrioventricular delay pacing has been documented
in many previous studies127'28-301 and these results have
been confirmed. As we investigated patients with and
without an acute gradient reduction (Groups A and B)
and found no difference between them, the relationship
between maximal gradient and severity of symptoms
must be held in doubt. It would seem that pressure
gradient reduction by pacing is not the only factor
which explains the efficacy of pacing in hypertrophic
obstructive cardiomyopathy. This is in agreement with
earlier analysis of this disease where symptoms could not
be related to obstruction'3'1.
The experimental evidence of modification of
contractile behaviour'321, of improved capillary coronary
flow'331 and remodelling of the ventricle'341 with ectopic
stimulation may, in part, explain our results. Reduction
of wall-stress, of mitral regurgitation and prolongation
of systolic ejection time all contribute to the benefit of
pacing, although not analysed in detail in this report.
As hypertrophic obstructive cardiomyopathy causes
important diastolic dysfunction1351, pacing might also
influence this. However, only detailed subgroup analysis
of our echocardiographic findings will elucidate this
aspect. Currently only the segmental wall motion
changes are an evident feature'361. The population
investigated in this study was considered primarily to
be candidates for surgery. However, they were not
extremely symptomatic as no Class IV patients were
included. It can therefore be concluded that pacing
relieves symptoms in most Class II and III patients who
are already on maximal tolerated drug therapy. As
pacing allows an increase in beta-blocking and calcium-
blocking therapy without the risk of extreme brady-
cardia, a further benefit of pacing to be considered might
be by further optimization of drug treatment; however,
the opposite may also be true. Symptomatic relief
induced by cardiac pacing may allow patients to be
cared for without pharmacological support. Some of the
drugs used to treat hypertrophic obstructive cardiomy-
opathy, and in particular at dosages frequently admin-
istered, may be badly tolerated. Patients may suffer side
effects of the drugs rather than symptoms of the cardiac
disease itself. Further investigations should look at this
possibility.
The effect of pacing depends on full ventricular
capture together with appropriately timed left atrial
contribution to left ventricular filling'271. Achievement of
an atrioventricular delay which both optimizes atrio-
ventricular synchrony and provides complete ven-
tricular capture in some hypertrophic obstructive
cardiomyopathy patients can be difficult and one might
consider atrioventricular nodal ablation. In fact, further
improvement in pacemaker benefit may be achieved by
atrioventricular node ablation in patients with a short
intrinsic atrioventricular delay'37381. One of the advan-
tages of pacing is that it does not prevent use of other
available treatments and is reversible as leads and pace-
makers can be removed; this is in contrast to chemical
ablation'391 where there is inevitably an irreversible
infarcted area. Failure of pacing still allows surgery to
be considered, and three of the study patients finally
underwent this intervention. Although our patient
population seems slightly less symptomatic than recently
published surgical series'40'4'1, the results compare
favourably with these non-randomized retrospective
analyses. However, pacemaker treatment is not without
complications and the high incidence reported in
this series is at variance with generally accepted stan-
dards. The relatively high level of complications may
reflect this, being the first prospective multi-centre
study investigating pacemaker treatment, or that
the hypercontractile ventricles in hypertrophic obstruc-
tive cardiomyopathy hearts are more likely to be associ-
ated with electrode displacements. The one fatality
reported was due to right ventricular perforation, a
recognised but rare complication of pacing that
was diagnosed too late and therefore led to cardiac
tamponade.
Limitations of the study
Hypertrophic obstructive cardiomyopathy is character-
ized by symptoms and objective parameters that are
variable and, with the exception of the gradient, difficult
to assess accurately. This study only investigated a
subgroup of hypertrophic cardiomyopathy patients
which comprises approximately 5-10% of all patients
with this disease'42', but might nevertheless contribute
to judgement. Although symptomatic, many patients
showed quite good exercise tolerance despite their
V02rnax being reduced but further analysis on these
investigations will follow. Quality of life assessments
with a standardized questionnaire seemed the appropri-
ate technique to judge objectively subjective criteria, as it
has been validated for other diseases, such as cancer'43'.
The study design was double-blind, but when program-
ming a pacemaker, looking at an echocardiogram and
at an ECG during exercise testing complete blinding of
the medical personnel might be incomplete. The quality
of life questionnaire was filled out by nurses who
were not informed of the pacing mode in operation; thus
this aspect of the study was also double blind. At
this point the study cannot answer questions about
recurrent syncope, arrhythmias or sudden death but
the patients will be followed and more information will
be reported with a follow-up period long enough to
address these topics as well as echocardiographic
substudies.
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Conclusions
We have shown that dual-chamber pacing is a useful
complement to drug treatment in symptomatic hyper-
trophic obstructive cardiomyopathy. It significantly
reduces outflow obstruction in all and improved
symptoms in 84% of patients while increasing exercise
tolerance by 21% in those severely limited.
The study design allowed the device and invasive
procedure to be tested blindly for the first time. Short
atrioventricular delay (below 100 ms) pacing, therefore,
can be recommended in patients corresponding to our
selection criteria. However, further critical investigations
are needed to identify the major underlying mechanisms
of the beneficial effect of pacing in order to best define
the patient who will have the greatest benefit from this
new treatment.
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